Table 2.
Absolute incidence of cardiovascular disease outcomes at specific timepoints after cancer diagnosis compared with expected incidence, by age group
|
18–59 years |
60–79 years |
≥80 years |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Observed incidence | Expected incidence | Excess (95% CI) | Observed incidence | Expected incidence | Excess (95% CI) | Observed incidence | Expected incidence | Excess (95% CI) | |
| Arrhythmia incidence at 5 years | |||||||||
| Colorectal (C18–20) | 1·2 | 1·0 | 0·2 (−0·0 to 0·5) | 2·5 | 2·3 | 0·2 (−0·0 to 0·5) | 4·2 | 4·6 | −0·4 (−1·1 to 0·3) |
| Lung (C34) | 2·7 | 1·0 | 1·7 (0·8 to 2·6) | 3·9 | 2·5 | 1·4 (0·6 to 2·2) | 6·1 | 5·4 | 0·7 (−1·4 to 2·7) |
| Melanoma (C43) | 1·0 | 0·8 | 0·1 (−0·1 to 0·3) | 2·1 | 2·0 | 0·1 (−0·3 to 0·4) | 3·9 | 4·0 | −0·2 (−1·2 to 0·8) |
| Breast (C50) | 1·1 | 1·0 | 0·1 (−0·0 to 0·2) | 1·9 | 1·8 | 0·1 (−0·1 to 0·2) | 3·8 | 3·7 | 0·1 (−0·4 to 0·6) |
| Uterus (C54–55) | 1·4 | 1·2 | 0·2 (−0·2 to 0·6) | 2·0 | 2·1 | −0·0 (−0·5 to 0·4) | 5·1 | 4·1 | 1·0 (−0·9 to 2·9) |
| Prostate (C61) | 1·1 | 1·1 | −0·0 (−0·3 to 0·2) | 2·6 | 2·5 | 0·1 (−0·1 to 0·3) | 5·5 | 5·0 | 0·5 (−0·2 to 1·1) |
| Bladder (C67) | 1·1 | 1·1 | 0·0 (−0·3 to 0·4) | 2·8 | 2·5 | 0·3 (−0·1 to 0·7) | 5·1 | 4·9 | 0·3 (−0·7 to 1·2) |
| NHL (C82–85) | 1·3 | 0·8 | 0·5 (0·1 to 0·9) | 2·9 | 2·1 | 0·8 (0·2 to 1·4) | 5·7 | 4·4 | 1·4 (−0·3 to 3·0) |
| Leukaemia (C91–95) | 1·1 | 1·0 | 0·2 (−0·2 to 0·6) | 2·6 | 2·4 | 0·2 (−0·4 to 0·8) | 3·9 | 5·0 | −1·1 (−2·4 to 0·2) |
| Coronary artery disease incidence at 5 years | |||||||||
| Colorectal (C18–20) | 0·7 | 0·6 | 0·1 (−0·1 to 0·2) | 1·3 | 1·4 | −0·2 (−0·4 to 0·0) | 2·2 | 2·3 | −0·1 (−0·5 to 0·4) |
| Lung (C34) | 1·3 | 0·7 | 0·6 (0·0 to 1·2) | 2·0 | 1·7 | 0·3 (−0·3 to 0·9) | 2·9 | 2·7 | 0·2 (−1·2 to 1·5) |
| Melanoma (C43) | 0·3 | 0·3 | 0·0 (−0·1 to 0·1) | 1·2 | 0·9 | 0·3 (0·0 to 0·6) | 2·1 | 1·9 | 0·2 (−0·6 to 1·0) |
| Breast (C50) | 0·3 | 0·3 | −0·0 (−0·1 to 0·0) | 0·8 | 0·9 | −0·1 (−0·2 to 0·0) | 1·3 | 1·7 | −0·4 (−0·7 to −0·1) |
| Uterus (C54–55) | 0·4 | 0·4 | −0·0 (−0·3 to 0·2) | 0·7 | 1·0 | −0·4 (−0·6 to −0·1) | 2·3 | 1·9 | 0·4 (−0·8 to 1·6) |
| Prostate (C61) | 0·9 | 1·0 | −0·1 (−0·4 to 0·1) | 1·8 | 1·8 | 0·1 (−0·1 to 0·2) | 2·6 | 2·7 | −0·1 (−0·5 to 0·3) |
| Bladder (C67) | 1·1 | 0·7 | 0·4 (0·1 to 0·7) | 2·0 | 1·7 | 0·4 (0·0 to 0·7) | 2·7 | 2·6 | 0·2 (−0·5 to 0·8) |
| NHL (C82–85) | 0·8 | 0·4 | 0·3 (0·1 to 0·6) | 1·8 | 1·3 | 0·5 (0·1 to 1·0) | 2·2 | 2·0 | 0·2 (−0·7 to 1·2) |
| Leukaemia (C91–95) | 0·9 | 0·6 | 0·3 (−0·1 to 0·7) | 1·8 | 1·5 | 0·4 (−0·2 to 0·9) | 3·1 | 2·0 | 1·1 (−0·1 to 2·2) |
| Heart failure or cardiomyopathy incidence at 5 years | |||||||||
| Colorectal (C18–20) | 0·3 | 0·3 | 0·0 (−0·1 to 0·1) | 1·0 | 1·1 | −0·0 (−0·2 to 0·1) | 2·6 | 3·0 | −0·4 (−0·9 to 0·1) |
| Lung (C34) | 1·1 | 0·3 | 0·8 (0·3 to 1·3) | 2·2 | 1·3 | 0·8 (0·3 to 1·4) | 4·1 | 4·1 | 0·1 (−1·5 to 1·6) |
| Melanoma (C43) | 0·1 | 0·1 | −0·0 (−0·1 to 0·0) | 0·6 | 0·7 | −0·1 (−0·3 to 0·1) | 2·3 | 2·5 | −0·2 (−0·9 to 0·5) |
| Breast (C50) | 0·2 | 0·1 | 0·1 (0·1 to 0·2) | 0·7 | 0·7 | 0·1 (−0·0 to 0·2) | 2·1 | 2·3 | −0·1 (−0·5 to 0·2) |
| Uterus (C54–55) | 0·2 | 0·2 | −0·0 (−0·1 to 0·1) | 0·7 | 0·8 | −0·1 (−0·3 to 0·2) | 3·3 | 2·7 | 0·6 (−0·7 to 1·9) |
| Prostate (C61) | 0·4 | 0·4 | −0·1 (−0·2 to 0·1) | 1·4 | 1·4 | 0·0 (−0·1 to 0·2) | 4·0 | 3·6 | 0·3 (−0·2 to 0·8) |
| Bladder (C67) | 0·4 | 0·3 | 0·1 (−0·1 to 0·3) | 1·7 | 1·5 | 0·3 (0·0 to 0·5) | 4·2 | 3·9 | 0·3 (−0·5 to 1·1) |
| NHL (C82–85) | 0·6 | 0·2 | 0·4 (0·2 to 0·6) | 1·8 | 0·9 | 1·0 (0·6 to 1·3) | 4·6 | 2·5 | 2·1 (0·8 to 3·3) |
| Leukaemia (C91–95) | 0·5 | 0·2 | 0·3 (0·0 to 0·5) | 1·6 | 1·1 | 0·5 (0·1 to 0·9) | 3·8 | 3·5 | 0·4 (−0·8 to 1·5) |
| Stroke incidence at 5 years | |||||||||
| Colorectal (C18–20) | 0·4 | 0·3 | 0·1 (−0·0 to 0·2) | 1·1 | 1·1 | −0·0 (−0·2 to 0·1) | 2·1 | 2·5 | −0·4 (−0·8 to 0·0) |
| Lung (C34) | 1·1 | 0·3 | 0·8 (0·4 to 1·3) | 1·6 | 1·3 | 0·4 (−0·0 to 0·8) | 2·6 | 2·6 | 0·0 (−1·0 to 1·1) |
| Melanoma (C43) | 0·3 | 0·2 | 0·1 (−0·0 to 0·2) | 0·8 | 0·8 | −0·0 (−0·2 to 0·2) | 1·9 | 2·1 | −0·2 (−0·9 to 0·5) |
| Breast (C50) | 0·2 | 0·2 | 0·0 (−0·0 to 0·1) | 0·8 | 0·7 | 0·0 (−0·1 to 0·1) | 2·0 | 2·1 | −0·1 (−0·5 to 0·2) |
| Uterus (C54–55) | 0·2 | 0·2 | −0·0 (−0·2 to 0·1) | 0·7 | 0·8 | −0·0 (−0·3 to 0·2) | 1·8 | 1·7 | 0·1 (−0·8 to 1·0) |
| Prostate (C61) | 0·6 | 0·5 | 0·1 (−0·0 to 0·3) | 1·3 | 1·2 | 0·0 (−0·1 to 0·2) | 2·6 | 2·5 | 0·1 (−0·3 to 0·5) |
| Bladder (C67) | 0·4 | 0·3 | 0·1 (−0·1 to 0·3) | 1·4 | 1·3 | 0·1 (−0·2 to 0·3) | 3·0 | 2·8 | 0·2 (−0·5 to 0·8) |
| NHL (C82–85) | 0·4 | 0·2 | 0·2 (0·0 to 0·4) | 1·2 | 1·0 | 0·2 (−0·1 to 0·6) | 2·9 | 2·4 | 0·5 (−0·5 to 1·6) |
| Leukaemia (C91–95) | 0·6 | 0·3 | 0·3 (0·1 to 0·6) | 1·2 | 0·9 | 0·3 (−0·1 to 0·6) | 2·0 | 2·3 | −0·3 (−1·1 to 0·5) |
| Venous thromboembolism incidence at 1 year | |||||||||
| Colorectal (C18–20) | 1·5 | 0·1 | 1·4 (0·9 to 1·8) | 2·0 | 0·3 | 1·7 (1·2 to 2·1) | 2·0 | 0·6 | 1·4 (0·8 to 1·9) |
| Lung (C34) | 4·5 | 0·2 | 4·3 (2·9 to 5·8) | 3·8 | 0·5 | 3·3 (2·4 to 4·2) | 3·1 | 0·8 | 2·3 (0·9 to 3·7) |
| Melanoma (C43) | 0·3 | 0·1 | 0·3 (0·1 to 0·4) | 0·8 | 0·2 | 0·6 (0·2 to 1·0) | 1·0 | 0·4 | 0·5 (−0·1 to 1·2) |
| Breast (C50) | 0·7 | 0·1 | 0·6 (0·5 to 0·8) | 1·1 | 0·3 | 0·9 (0·7 to 1·1) | 1·7 | 0·5 | 1·2 (0·7 to 1·6) |
| Uterus (C54–55) | 1·3 | 0·2 | 1·2 (0·4 to 2·0) | 2·3 | 0·3 | 1·9 (0·8 to 3·1) | 3·0 | 0·8 | 2·3 (0·3 to 4·2) |
| Prostate (C61) | 0·4 | 0·2 | 0·2 (0·1 to 0·4) | 0·9 | 0·3 | 0·5 (0·3 to 0·8) | 1·3 | 0·5 | 0·8 (0·3 to 1·2) |
| Bladder (C67) | 1·2 | 0·1 | 1·1 (0·5 to 1·7) | 1·9 | 0·3 | 1·6 (0·9 to 2·4) | 1·7 | 0·5 | 1·2 (0·5 to 1·9) |
| NHL (C82–85) | 0·7 | 0·1 | 0·6 (0·0 to 1·2) | 1·4 | 0·3 | 1·1 (0·0 to 2·1) | 1·7 | 0·7 | 1·0 (−0·4 to 2·4) |
| Leukaemia (C91–95) | 0·4 | 0·1 | 0·3 (−0·0 to 0·6) | 0·8 | 0·4 | 0·4 (−0·2 to 0·9) | 0·8 | 0·7 | 0·2 (−0·6 to 0·9) |
| Venous thromboembolism incidence at 5 years | |||||||||
| Colorectal (C18–20) | 0·8 | 0·2 | 0·6 (0·4 to 0·7) | 1·0 | 0·5 | 0·5 (0·3 to 0·6) | 1·0 | 1·0 | 0·0 (−0·2 to 0·3) |
| Lung (C34) | 1·7 | 0·2 | 1·5 (0·8 to 2·2) | 1·4 | 0·6 | 0·9 (0·4 to 1·4) | 1·2 | 0·9 | 0·2 (−0·4 to 0·9) |
| Melanoma (C43) | 0·3 | 0·1 | 0·1 (0·0 to 0·2) | 0·6 | 0·5 | 0·2 (−0·0 to 0·4) | 0·8 | 0·9 | −0·2 (−0·6 to 0·2) |
| Breast (C50) | 0·5 | 0·2 | 0·4 (0·3 to 0·4) | 0·8 | 0·4 | 0·4 (0·3 to 0·5) | 1·2 | 0·8 | 0·4 (0·1 to 0·6) |
| Uterus (C54–55) | 0·5 | 0·2 | 0·3 (0·1 to 0·5) | 0·9 | 0·5 | 0·4 (0·1 to 0·7) | 1·2 | 1·0 | 0·1 (−0·6 to 0·8) |
| Prostate (C61) | 0·4 | 0·2 | 0·2 (0·0 to 0·3) | 0·9 | 0·5 | 0·4 (0·2 to 0·5) | 1·3 | 0·8 | 0·5 (0·2 to 0·8) |
| Bladder (C67) | 0·6 | 0·2 | 0·3 (0·1 to 0·5) | 0·9 | 0·5 | 0·3 (0·2 to 0·5) | 0·8 | 0·9 | −0·1 (−0·4 to 0·2) |
| NHL (C82–85) | 0·5 | 0·2 | 0·3 (0·1 to 0·5) | 0·9 | 0·5 | 0·4 (0·1 to 0·7) | 1·1 | 1·0 | 0·0 (−0·6 to 0·6) |
| Leukaemia (C91–95) | 0·7 | 0·2 | 0·5 (0·1 to 0·8) | 1·2 | 0·6 | 0·6 (0·2 to 1·0) | 1·3 | 1·0 | 0·3 (−0·3 to 1·0) |
Data are absolute incidence (from time of cancer diagnosis) of cardiovascular disease outcomes per 100 person-years (or equivalently risk [%] per year). Cancer codes from the International Classification of Diseases, version 10. Incidence in cancer survivors and expected incidence calculated by fitting flexible parametric survival models with exposure (cancer survivor vs control), covariates, and interaction between exposure and time since diagnosis and predicting incidence for exposed or unexposed at the mean value of covariates in cancer survivors. NHL=non-Hodgkin lymphoma.